Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma (original) (raw)

Clinical Oncology/Epidemiology

British Journal of Cancer volume 68, pages 767–774 (1993)Cite this article

Abstract

One hundred and eighteen consecutive adults with newly diagnosed intermediate and high-grade non-Hodgkin's lymphoma were treated with chemotherapy comprising Doxorubicin, Cyclophosphamide, Vincristine and Prednisolone with mid-cycle Methotrexate (MTX) and leucovorin rescue ('CHOP-M'). Intrathecal MTX was given with each treatment cycle as central nervous system (CNS) prophylaxis. 'Clinical remission' was achieved in 70/110 evaluable patients (64%), complete remission: 45/110, (41%), good partial remission: 25/110 (23%). Twenty two patients (19%) died prior to completion of therapy, 18 patients had persistent disease. Hyponatremia (< 137 mmol l-1), advanced age and hypoalbuminaemia (< 32 g l-1) correlated adversely with achievement of CR (P = 0.0007, 0.0005 and 0.04 respectively). With a minimum follow up of 41 years, 47 of the seventy patients (67%) in whom clinical remission was achieved remain well, 19 have developed recurrent disease, resulting in an actuarial projected remission duration of 70% at 8 years. Four died in CR. There has been only one isolated CNS recurrence. On univariate analysis, hypoalbuminaemia, hyponatremia and beta 2 microglobulin (> 3) correlated with unfavourable outcome in terms of duration of remission (P = 0.0009, 0.007 and 0.04 respectively). On multivariate analysis, only the serum sodium (0.002) and advanced age (0.01) were predictive for remission duration. Fifty patients (45%) are alive, the overall actuarial projected survival is thus 42% at 8 years. On univariate analysis, age, hypoalbuminaemia, hyponatraemia, liver involvement and the presence of B symptoms correlated unfavourably with survival. On multivariate analysis, hypoalbuminaemia, advanced age, hyponatraemia, male gender (aged > 50) and diffuse large cell or large cell, immunoblastic histology (Working Formulation) had an adverse effect (P = 0.003, < 0.0001, < 0.0001, 0.002, and 0.03). It was further possible, using cut-off points of 32 g l-1 and 136 mmol l-1 for albumin and sodium respectively to define prognostic categories for patients who differed significantly in terms of survival.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. ICRF Department of Medical Oncology, St Bartholomew's Hospital, London, UK
    HS Dhaliwal

Authors

  1. HS Dhaliwal
  2. AZS Rohatiner
  3. W Gregory
  4. MA Richards
  5. PWM Johnson
  6. JS Whelan
  7. CJ Gallagher
  8. J Matthews
  9. TS Ganesan
  10. MJ Barnett
  11. JH Waxman
  12. AG Stansfeld
  13. PFM Wrigley
  14. ML Slevin
  15. JS Malpas
  16. TA Lister

Rights and permissions

About this article

Cite this article

Dhaliwal, H., Rohatiner, A., Gregory, W. et al. Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.Br J Cancer 68, 767–774 (1993). https://doi.org/10.1038/bjc.1993.425

Download citation

This article is cited by